Neko Health raises $700M as demand grows for preventive health scans

Neko Health today announced the completion of its $700 million  Series C funding round. 

The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from existing investors Atomico, General Catalyst, and Lakestar, alongside new backers including Liberty City Ventures, Positive Sum, and BDT & MSD.  The fundraise follows a $260 million Series B in January 2025.  

Founded by Spotify's Daniel Ek and Hjalmar Nilsonne, Neko Health is a health technology company redefining how people understand and act on their health.

At the heart of Neko’s offering is the Neko Health Scan, a 60-minute, comprehensive,  non-invasive, and radiation-free health assessment that captures millions of health data points, priced at £299 in the UK and 2,750 SEK in Sweden. 

Using proprietary sensors alongside blood analysis, the scan assesses skin health, including moles and marks,  biomarkers to identify pre-diabetes risk, as well as blood abnormalities and risk factors linked to metabolic syndrome, stroke, and heart attack. Results are delivered on-site within minutes and discussed during an in-person consultation with a medical professional,  providing members with personalised and actionable health findings.  

Today's news comes three weeks after Neko's most significant scan advancement to date.  The addition of body composition measures, captured in seconds during the scan, and clinician review of wearable data, is now live across all clinics – giving members an even more detailed picture of their health both in the moment and between visits.  This is the latest step in a program of continuous innovation, made possible by Neko's ownership of every part of its tech stack in-house. 

Last month, Neko opened its latest clinic in Stockholm, built around the next generation of  Neko-engineered medical devices, Derma-2, Echo-2, and Spectrum-2, each upgraded to capture a greater volume and higher fidelity of health signals across skin, heart, and circulation, with increased automation freeing up clinical staff to focus on member care. This hardware will be rolled out across all Neko clinics in the next few months.  

According to Hjalmar Nilsonne, Neko Health Co-Founder and CEO:

"With this round,  we're taking our mission to the US for the first time, while continuing to invest in the  research and technology that make prevention possible at scale. The clearest proof is in our  members: the vast majority of our members return after their first scan, and when they do,  their health markers move in the right direction."

Bejul Somaia, Global Partner, Lightspeed Venture Partners, said: 

"Over the past eighteen months, Neko Health has demonstrated remarkable innovation and growth, attacking one of the largest markets in the world with breakthrough technology,  proven consumer demand, and a clear path to global scale.

We believe this is one of the  most important healthcare companies of our generation, and we're proud to deepen our  partnership as they continue to reimagine prevention." 

"For more than 20 years, I've tracked every metric imaginable to optimise health and performance. It’s expensive, complicated, and fragmented. I’ve invested in Neko because  they offer beautiful simplicity, and only simplicity scales: you get a high-definition map of your biology in less than 60 minutes, explained by an unhurried doctor, all in one location and for £299. No one else can do this. And believe me, as I’ve toured their R&D lab in  Sweden: there’s a lot more coming,” says Tim Ferriss, bestselling author of The 4-Hour  Body, which introduced millions to data-driven personal health, including continuous glucose monitors, DEXA, and other technologies. 

Since launching in February 2023, Neko Health has expanded its footprint in Sweden and the UK, including Manchester, Birmingham, and multiple locations in London (Marylebone, Spitalfields, Covent Garden, Victoria). Over 350,000 people have registered for a Neko  Health Scan, and more than 100,000 members have already experienced one. On average, 75 per cent of members book and prepay for a scan for the following year at the end of their appointment.  

According to its latest health data, early detection is translating into measurable health improvements for returning members. Neko Health found that three in four returning members with previously identified severe or life-threatening conditions were in good health or had their conditions under control. Overall, five of seven key biomarkers showed statistically significant improvement between Scan 1 and Scan 2. 

As part of the round, David Ofer of O.G. Venture Partners will join the Board of Directors, subject to regulatory approval.